Research Article By Dr. H. R. Edraki, RADOIR’s Managing Director: “ Fetal MRI in Early Diagnosis in Brain Disorders” Published By MRI International Book.
By Ed Miseta, Chief Editor, Clinical Leader
Patient recruitment has always been challenge for companies conducting clinical trials. Knowing how to properly engage with advocacy groups can determine whether they will treat you as a trusted partner or a necessary evil.
Using both CRISPR-Cas9 and base editor 3 (BE3) gene-editing tools, the team reduced cholesterol levels in healthy mice treated in utero by targeting a gene that regulates those levels. Also used prenatal gene editing to improve liver function and prevent neonatal death in a subgroup of mice that had been engineered with a mutation causing the lethal liver disease hereditary tyrosinemia type 1 (HT1).
In a study at seven hospitals across the UK and the USA, researchers found the brain scan, called magnetic resonance (MR) spectroscopy. Brain damage affects around one in 300 births in the UK, and is usually caused by oxygen deprivation.
Since it can take 5 to 7 years for a patient with a rare disease to receive an accurate diagnosis—which can be the gateway to appropriate treatments and access to life-saving clinical trials—a panel at this year’s National Organization of Rare Diseases’ Rare Diseases & Orphan Products Breakthrough Summit (NORD Summit) held in Washington, DC, delved into specific associated challenges and how providers might overcome them.
Researchers from The Rockefeller University recently uncovered the molecular mechanism which causes individuals with a rare skin condition to be susceptible to human papillomavirus (HPV).
Senator Hatch and Representatives Lance and Butterfield introduced a resolution that heralds the success of the Orphan Drug Act (ODA) and calls for continued support of the legislation.
This year marks the 35th anniversary for the ODA. That means 35 years of increased hope and treatments for the rare disease community. Prior to the ODA, there were only 34 therapies indicated to treat a rare disease. Now, there are over 700 and counting!
A university of Houston pharmaceutical scientist is developing a drug which could bring relief to children suffering with Familial Adenomatous Polyposis (FAP), a rare genetic disorder characterized by hundreds if not thousands of colorectal polyps. This hereditary cancer predisposition syndrome occurs in 3 per 100000 live births and, if left untreated, causes colorectal cancer in patients nearly 100 percent of the time. Prior medication for the diseases failed because it increased the risk of heart attacks and death.